Antibody-drug conjugates (ADCs) are among the most promising and complex modalities in oncology today. Combining highly potent payloads with aseptic drug product manufacturing creates unique challenges around containment, sterility, product stability, and supply reliability. In this white paper, our experts Paul Delafon and Peter Tiefenboeck share how Lonza’s integrated ADC drug product capabilities help customers navigate this complexity with confidence, from development through commercial supply.
In this white paper, you will learn:
- Why ADC drug product manufacturing requires a careful balance between containment, sterility, and product stability.
- How advanced isolator technologies and engineered containment strategies help reduce risk while protecting product integrity.
- Approaches to managing sensitive ADC molecules through precise environmental controls, tailored process design, and specialized manufacturing expertise.
- How flexible manufacturing platforms support both lyophilized and liquid presentations, enabling greater choice across clinical and commercial programs.
- The advantages of an integrated end-to-end ADC model, connecting antibody production, payload-linker capabilities, bioconjugation, and drug product manufacturing within a single organization.
